Content Type: Commentary & Opinion

Op-Ed: New Alzheimer’s Drug Is a Problem for FDA’s Pass-Fail Approach

March 6, 2026

Congress’ Misguided Plan to Ban QALYs

March 6, 2026

Eroding Judicial Deference to the FDA—Consequences for Public Health

March 6, 2026

Op-Ed: Not So Fast on COVID Vaccine Price Hike

March 6, 2026

Op-Ed: Is It Business as Usual for the Drug Industry?

March 6, 2026

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma

March 6, 2026

Two Views of Cancer Medicines: Imagery Versus Evidence

March 6, 2026

Surrogate Measures of Drug Efficacy—A Finger Pointing at the Moon

March 6, 2026

Melflufen: Post-Hoc Subgroup Analyses and the US FDA Oncologic Drugs Advisory Committee

March 6, 2026

Concerns About Climate Activism in Clinical Practice (Reply)

March 6, 2026

The Right to Repair Software-Dependent Medical Devices

March 6, 2026

Climate Change and the Prescription Pad

March 6, 2026